stars 1 stars 2 stars 3

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/

Merus N.V. Questions

The Merus N.V. annual revenue was $35.9 million in 2026.

John de Kruif is the CTO of Merus N.V..

135 people are employed at Merus N.V..

Merus N.V. is based in Utrecht, Utrecht.

The NAICS codes for Merus N.V. are [62151, 32541, 3254, 32, 325, 325414, 62, 6215, 621].

The SIC codes for Merus N.V. are [283, 28].

Top Merus N.V. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users